These results suggested that CAFs are required to promote CCA growth and LNM, and the PDGF-BB/PDGFR-β signaling pathway is crucial for CAFs to exert their promoting role, demonstrating their potential as a therapeutic target. This evidence concerns the gene PDGFRB and cholangiocarcinoma.